Publications

In vitro activity of meropenem/RPX7009, a carbapenem/ß-lactamase inhibitor combination against contemporary populations of Enterobacteriaceae and KPC-producing strains, Lead author: Castanheira M, presented at ID Week, October 8 – 12, 2014, Philadelphia, PA

Antimicrobial Activity of Ceftolozane/Tazobactam Tested against Gram-negative Bacterial Isolates from Hospitalized Patients with Pneumonia in United States Hospitals (2013), Lead author: Farrell DJ, presented at ID Week, October 8 – 12, 2014, Philadelphia, PA

Antifungal susceptibility patterns of a global collection of fungal isolates and polysorbate-80 effect on the susceptibility of the antifungal classes, Lead author: Castanheira M, presented at ID Week, October 8 – 12, 2014, Philadelphia, PA

Oritavancin Activity Against Gram-positive Clinical Isolates Responsible for Documented Skin and Skin Structure Infections in USA and European Hospitals (2012-2013), Lead author: Mendes RE, presented at ID Week, October 8 – 12, 2014, Philadelphia, PA

Differences in Potency and Categorical Agreement between COL and Poly B against 15,377 Strains Collected WW, Lead author: Sader HS, presented at ID Week, October 8 – 12, 2014, Philadelphia, PA

Activity of ceftaroline against respiratory tract infection (RTI) pathogens isolated from USA medical centers in 2013, Lead author: Sader HS, presented at ID Week, October 8 – 12, 2014, Philadelphia, PA

Telavancin (TLV) In vitro Activity Tested Against a USA Collection of Methicillin-resistant Staphylococcus aureus (MRSA), Including a Multidrug-resistant (MDR) Subset (2011-2013), Lead author: Mendes RE, presented at ID Week, October 8 – 12, 2014, Philadelphia, PA

Antimicrobial Activity and Spectrum of Ceftaroline Tested Against Bacterial Isolates Causing Skin and Skin Structure Infections (SSSI) in United States (USA) Medical Centers, Lead author: Sader HS, presented at ID Week, October 8 – 12, 2014, Philadelphia, PA

Activity of the Novel Bacterial Topoisomerase II Inhibitor, GSK2140944, Against Select Gram-positive and Gram-negative Bacteria, Lead author: Flamm R, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

In Vitro Spectrum of Pexiganan Against Pathogens from Diabetic Foot Infections and with Selected Resistance Mechanisms, Lead author: Flamm R, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Serotype Distributions and Susceptibility Profiles of Streptococcus pneumoniae Associated with Noninvasive Infections in Adult Patients in the United States (2009-2012), Lead author: Mendes RE, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Antimicrobial Activity of Ceftolozane/Tazobactam (TOL/TAZ) and Comparator Agents Tested against Pseudomonas aeruginosa Isolates from United States (USA) Medical Centers (2013), Lead author: Farrell DJ, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Ceftaroline Activity Tested against Bacterial Pathogens Frequently Isolated in United States (USA) Medical Centers: Results from 5 Years of AWARE Surveillance Program, Lead author: Sader HS, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Multiple Mutations in the Quinolone Resistance Determining Regions (QRDR) Detected Among Fluoroquinolone-Resistant Haemophilus parainfluenzae Collected in the USA, Lead author: Castanheira M, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Carbapenemases-producing Enterobacteriaceae in 2013: increasing prevalence of multiple carbapenemases in single isolates, expansion of OXA-48-producers and a new KPC-variant, Lead author: Castanheira M, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Ceftolozane/Tazobactam Activity Tested against Contemporary (2013) Enterobacteriaceae Strains Causing Infections in United States (USA) Medical Centers, Lead author: Farrell DJ, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Oritavancin Activity against Gram-positive Pathogens Responsible for Documented Infections in US Hospitals (2012-2013), Lead author: Mendes RE, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Update of the Telavancin Activity in vitro Tested Against a Worldwide Collection of Gram-positive Clinical Isolates (2013), When Applying the Revised Susceptibility Testing Method, Lead author: Mendes RE, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Surrogate Analysis of Vancomycin to Predict Susceptible Categorization of Dalbavancin, Lead author: Jones RN, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Analysis of Vancomycin as a Surrogate Agent for Presumptive Susceptibility Categorization for Telavancin, Lead author: Mendes RE, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Contemporary Arbekacin Activity When Tested against Clinical Bacteria Isolated from Patients Hospitalized with Pneumonia in United States (USA) Hospitals, Lead author: Sader HS, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

TD-1607 Tested against Well Characterized Resistant Subsets of Staphylococcus spp., Lead author: Sader HS, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Arbekacin Tested against Well Characterized Multidrug-Resistant (MDR) Gram-negative Bacilli and Methicillin-Resistant Staphylococcus aureus (MRSA), Lead author: Sader HS, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

In vitro activity of RX-P873 tested against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter spp., Lead author: Flamm R, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Activity of a novel echinocandin biafungin (CD101) tested against most common Candida and Aspergillus species, including echinocandin- and azole-resistant strains, Lead author: Castanheira M, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Isavuconazole and Nine Comparator Antifungal Susceptibility Profiles for Common and Uncommon Opportunistic Fungi Collected in 2013: Application of New Clinical Breakpoints and Epidemiological Cutoff Values, Lead author: Pfaller MA, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Antimicrobial Activity of Ceftaroline Tested against Staphylococcus aureus from Surgical Skin and Skin Structure Infections in USA Medical Centers, Lead author: Sader HS, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Antimicrobial Activity of TD-1607 Tested against Contemporary (2010-2012) Methicillin-Resistant Staphylococcus aureus (MRSA) Strains, Lead author: Sader HS, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Accuracy of Sensititre dry-form broth microdilution panels to determine ceftaroline-avibactam MIC values, Lead author: Jones RN, presented at 114th annual American Society for Microbiology General Meeting (ASM), May 17 – 20, 2014, Boston, MA

Susceptibility testing of isolates displaying elevated colistin MIC values using polysorbate-80 (P-80), Lead author: Castanheira M, presented at 114th annual American Society for Microbiology General Meeting (ASM), May 17 – 20, 2014, Boston, MA

Validation of a TREK diagnostic systems dry-form broth microdilution MIC product for testing ceftazidime-avibactam, Lead author: Jones RN, presented at 114th annual American Society for Microbiology General Meeting (ASM), May 17 – 20, 2014, Boston, MA

Klebsiella pneumoniae belonging to ST258 from a New York city hospital carrying KPC-2- and VIM-4-encoding genes: Report from the SENTRY antimicrobial surveillance program, Lead author: Castanheira M, presented at 114th annual American Society for Microbiology General Meeting (ASM), May 17 – 20, 2014, Boston, MA

Baseline activity of telavancin when tested against Gram-positive clinical isolates responsible for documented infections in USA hospitals (2011-2012) applying a revised susceptibility testing method, Lead author: Mendes RE, presented at 114th annual American Society for Microbiology General Meeting (ASM), May 17 – 20, 2014, Boston, MA

Quality control ranges for performance assessment of a revised broth microdilution susceptibility testing method for telavancin, Lead author: Ross JE, presented at 114th annual American Society for Microbiology General Meeting (ASM), May 17 – 20, 2014, Boston, MA

Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies, Lead author: Farrell DJ, presented at 114th annual American Society for Microbiology General Meeting (ASM), May 17 – 20, 2014, Boston, MA

Evaluation of EUCAST zone diameter breakpoints for Pseudomonas spp., Lead author: Ahman, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Global prevalence, genetics and clonal relatedness of macrolide resistance in Moraxella catarrhalis (2010-2012), Lead author: Farrell DJ, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

GSK2140944 MIC quality control ranges using a multi-laboratory study design, Lead author: Jones RN, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Antimicrobial activity of ceftolozane/tazobactam and comparator agents tested against P. aeruginosa isolates from 15 European countries and Israel (2011-2012), Lead author: Farrell DJ, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Carbapenem-resistant Klebsiella pneumoniae clinical isolate harbouring a blaIMP-4- and qnrS-carrying plasmid, as well as a conjugative blaKPC-2 plasmid, Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from European hospitals: Results from the SENTRY Program (2010-2013), Lead author: Sader HS, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Characterization of intrinsic Beta-lactam resistance mechanisms among contemporary ceftazidime non-susceptible Pseudomonas aeruginosa from USA hospitals, Lead author: Castanheira M, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Linezolid susceptibility surveillance in Europe for 2013: ZAAPS Program (5,076 strains), Lead author: Jones RN, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Telavancin activity tested against Gram-positive clinical isolates from European hospitals (2011-2013) using a revised broth microdilution testing method: Redefining the baseline activity for telavancin, Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae recovered principally from lower respiratory tract specimens in older adult patients (≥50 years of age) in select European countries (2009-2011), Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

KPC-producing Pseudomonas aeruginosa from the United States: What is next?, Lead author: Castanheira M, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Ceftolozane/tazobactam activity when tested against Gram-negative bacterial isolates from hospitalized patients with pneumonia in European hospitals (2011-2012), Lead author: Farrell DJ, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Activity of oritavancin tested against Gram-positive clinical isolates responsible for documented skin and soft tissue infections in European hospitals (2011-2013), Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Polymyxin B: Can we create a better product?, Lead author: Kassamali, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Antimicrobial activity of ceftolozane/tazobactam and comparator agents tested against Enterobacteriaceae isolates from 14 European countries and Israel (2012), Lead author: Farrell DJ, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain